Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 a-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 a-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach. J Mol Graph Model. 2020 12; 101:107730.